Juvenile Dermatomyositis Resistant to Steroids

Kaynakça (15)

1. Rider LG, Miller FW. Idiopathic inflammatory muscle disease: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 14: 37- 54, 2000
2. Ramanan AV, Feldman BM. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol 14: 658-62, 2002
3. Callen JP. Dermatomyositis: diagnosis, evaluation and management. Minerva Med 93: 157-67, 2002
4. Fisler RE, Liang MG, Fuhlbrigge RC et al. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 47: 505- 11, 2002
5. Wedderburn LR, Li CKC. Paediatric idiopathic inflammatory muscle disease. Best Pract Res Clin Rheumatol 18: 345–8, 2004
6. Pachman LM, Hayford JR, Chung A et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 25: 198–204, 1998
7. Pachman LM. Juvenile dermatomyositis. Pathophysiology and disease expression. Pediatr Clin North Am 42: 1071-98, 1995
8. Chandrasekaran AN, Rajendran CP, Thenmozhivalli PR et al. Spectrum of clinical and immunological features of systemic rheumatic diseases in a referral hospital in south India: juvenile dermatomyositis/polymyositis. J Indian Rheum Assoc 3: 141-3, 1995
9. Brottier L, Coste P, Combe C et al. Cardiac complications of dermatopolymyositis. Arch Mal Coeur Vaiss 80: 1133–8, 1987
10. Cloatre G, Sane M, Wade B et al. Cardiac manifestations of polymyositis. Apropos of 2 Senegalese cases. Rev Med Interne 19: 265-70, 1998
11. Soylu A, Kavukcu S, Turkmen M et al. Dermatomyositis with membranous nephropathy.Turk J Pediatr 43: 143-145, 2001
12. Pasquali JL, Meyer P, Christmann D et al. Renal manifestations in dermatomyositis and polymyositis. Ann Med Interne 138: 109- 113, 1987
13. Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. Am Acad Dermatol 36: 67-71, 1997
14. Zipitis CS, Baildam EM, Ramanan AV. Treatment approaches to juvenile dermatomyositis. Expert Opin Pharmacother 5: 1509- 15, 2004
15. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol 19: 138- 141, 2000.